ContractLicense Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 406 of the Securities Act of 1933, as amended. The confidential portions of this Exhibit that have been omitted are marked with “XXXX.” A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
Amendment No. 5 to the License Agreement dated 13th of June 2000 (the by and between Antares Pharma IPL AG Zug, Switzerland as Licensor (formerly known as Permatec Technologie AG) and BioSante Pharmaceuticals, Inc. Lincolnshire, IL, U.S.A. as LicenseeLicense Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, Antares Pharma IPL AG, Zug, Switzerland (“Antares”) and BioSante Pharmaceuticals, Inc., Lincolnshire, Illinois (“BioSante”) have previously entered into a License Agreement dated June 13, 2000 (“Agreement”), regarding the grant of a license with the right to sublicense specified products, as well as a Supply Agreement of the same date;
LICENSE AGREEMENT between PERMATEC TECHNOLOGIE, AG and BIOSANTE PHARMACEUTICALS, INC. [Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. The...License Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
This agreement is entered into, effective this 13th day of June, 2000, by and between PERMATEC TECHNOLOGIE, AG, a corporation of Switzerland (“PERMATEC”), and BIOSANTE PHARMACEUTICALS, INC., a Wyoming corporation (“BIOSANTE”).
ContractLicense Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. The confidential portions of this Exhibit that have been omitted are marked with “XXXX.” A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
CHANGE OF CONTROL AND SEVERANCE AGREEMENTChange of Control and Severance Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This Change of Control and Severance Agreement (this “Agreement”), effective as of July 16, 2008, is between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), located at 111 Barclay Boulevard, Suite 280, Lincolnshire, Illinois 60069 and Michael C. Snabes, M.D., Ph.D.(the “Employee”).
Amendment No. 6 to the License Agreement dated 13th of June 2000 by and between Antares Pharma IPL AG, Zug, Switzerland as Licensor (formerly known as Permatec Technologies AG) and BioSante Pharmaceuticals, Inc., Lincolnshire, IL, USA as LicenseeLicense Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, Antares Pharma IPL AG, Zug, Switzerland (“Antares”) and BioSante Pharmaceuticals, Inc., Lincolnshire, Illinois, United States of America (“BioSante”) have previously entered into a License Agreement dated June 13, 2000 (“License Agreement”), as amended in a series of five amendments, as follows: Amendment No. 1, dated May 20, 2001; Amendment No. 2, dated July 5, 2001; Amendment No. 3, dated August 30, 2001; Amendment No. 4, dated August 8, 2002; and Amendment No. 5, dated December 30, 2002 (collectively the Amendments and with the License Agreement, the “Agreement”); and
ContractLicense Agreement • March 16th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. The confidential portions of this Exhibit that have been omitted are marked with “XXXX.” A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
